ICU Medical, Inc. (NASDAQ:ICUI) CEO Vivek Jain sold 2,200 shares of the firm’s stock in a transaction dated Monday, October 9th. The shares were sold at an average price of $190.91, for a total value of $420,002.00. Following the sale, the chief executive officer now owns 44,111 shares in the company, valued at approximately $8,421,231.01. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Vivek Jain also recently made the following trade(s):

  • On Tuesday, October 10th, Vivek Jain sold 2,205 shares of ICU Medical stock. The shares were sold at an average price of $190.91, for a total value of $420,956.55.

Shares of ICU Medical, Inc. (NASDAQ ICUI) traded down 0.80% on Wednesday, hitting $187.05. The stock had a trading volume of 98,293 shares. The stock has a market cap of $3.71 billion, a PE ratio of 74.91 and a beta of 0.35. The company has a 50 day moving average price of $180.38 and a 200-day moving average price of $168.02. ICU Medical, Inc. has a 12 month low of $127.00 and a 12 month high of $192.65.

ICU Medical (NASDAQ:ICUI) last announced its earnings results on Wednesday, August 9th. The medical instruments supplier reported $0.52 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.58 by ($0.06). The business had revenue of $331.51 million for the quarter, compared to analysts’ expectations of $318.30 million. ICU Medical had a net margin of 6.10% and a return on equity of 7.56%. The firm’s quarterly revenue was up 242.8% compared to the same quarter last year. During the same quarter in the prior year, the company posted $1.15 earnings per share. On average, equities research analysts anticipate that ICU Medical, Inc. will post $4.11 earnings per share for the current year.

TRADEMARK VIOLATION WARNING: “Vivek Jain Sells 2,200 Shares of ICU Medical, Inc. (ICUI) Stock” was first posted by American Banking News and is the sole property of of American Banking News. If you are viewing this news story on another publication, it was illegally stolen and reposted in violation of U.S. & international trademark & copyright legislation. The correct version of this news story can be read at https://www.americanbankingnews.com/2017/10/11/vivek-jain-sells-2200-shares-of-icu-medical-inc-icui-stock.html.

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Piedmont Investment Advisors LLC purchased a new stake in ICU Medical in the 2nd quarter worth about $561,000. Ameritas Investment Partners Inc. raised its position in ICU Medical by 4.0% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 1,321 shares of the medical instruments supplier’s stock worth $228,000 after purchasing an additional 51 shares during the period. Castleark Management LLC purchased a new stake in ICU Medical in the 2nd quarter worth about $283,000. Bank of Nova Scotia purchased a new stake in ICU Medical in the 2nd quarter worth about $1,766,000. Finally, Raymond James Financial Services Advisors Inc. raised its position in ICU Medical by 29.2% in the 2nd quarter. Raymond James Financial Services Advisors Inc. now owns 11,404 shares of the medical instruments supplier’s stock worth $1,967,000 after purchasing an additional 2,574 shares during the period. Hedge funds and other institutional investors own 78.13% of the company’s stock.

ICUI has been the topic of a number of research reports. BidaskClub upgraded ICU Medical from a “hold” rating to a “buy” rating in a research report on Saturday, June 17th. Sidoti cut ICU Medical from a “buy” rating to a “neutral” rating in a research note on Tuesday, June 20th. Zacks Investment Research raised ICU Medical from a “hold” rating to a “strong-buy” rating and set a $195.00 price objective on the stock in a research note on Wednesday, July 12th. Finally, Gabelli reaffirmed a “buy” rating on shares of ICU Medical in a research note on Friday, August 11th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and one has assigned a buy rating to the stock. The company currently has an average rating of “Hold” and an average price target of $193.00.

ICU Medical Company Profile

ICU Medical, Inc is engaged in the development, manufacture and sales of medical devices used in infusion therapy, oncology and critical care applications. The Company’s product line includes needlefree connection devices, custom infusion sets, closed system transfer devices (CSTD) for the handling of hazardous drugs, advanced sensor catheters, needlefree closed blood sampling systems, disposable pressure transducer systems and hemodynamic monitoring systems.

Insider Buying and Selling by Quarter for ICU Medical (NASDAQ:ICUI)

Receive News & Ratings for ICU Medical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ICU Medical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.